Journal of Immigrant and Minority Health

, Volume 18, Issue 2, pp 292–300 | Cite as

Impact of Routine Quantiferon Testing on Latent Tuberculosis Diagnosis and Treatment in Refugees in Multnomah County, Oregon, November 2009–October 2012

Original Paper


Interferon-gamma release assays have potentially been transformative to screening programs focused on latent tuberculosis infection (LTBI) in foreign-born persons. We sought to add to this assessment by presenting the impact of a well-established refugee screening and treatment program switching from skin testing to Quantiferon®-TB Gold (QFT). We completed a retrospective cohort of refugees screened for tuberculosis between November 1, 2009–April 30, 2011 (pre-QFT) and May 1, 2011–October 31, 2012 (post-QFT). Among 2244 refugees screened that met the inclusion criteria, there was a significant difference in the proportion of refugees diagnosed with LTBI between the two time periods (p = <0.0001). In multivariate analysis, refugees tested with QFT had a greater odds of treatment initiation (adjusted odds ratio 1.53; 95 % CI 1.02–2.29, p = 0.040). However, test type had no impact on treatment completion (odds ratio 0.88; 95 % CI 0.57–1.36, p = 0.560). Although we demonstrated increased efficiency in LTBI diagnosis in this group, treatment completion rates indicate other barriers to treatment that must be addressed.


Tuberculosis Diagnosis Latent tuberculosis Refugee Treatment initiation Treatment completion 


  1. 1.
    Alami NN, Yuen CM, Miramontes R, Pratt R, Price SF, Navin TR, et al. Trends in tuberculosis—United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(11):229–33.PubMedGoogle Scholar
  2. 2.
    American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–47.Google Scholar
  3. 3.
    Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell TC. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010–October 2012. Am J Public Health. 2014;104(4):e95–102.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cain KP, Haley CA, Armstrong LR, Garman KN, Wells CD, Iademarco MF, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med. 2007;175(1):75–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002;346(19):1453–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005–2009. PLoS One. 2011;6(11):e27405.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hadzibegovic DS, Maloney SA, Cookson ST, Oladele A. Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis. 2005;9(4):409–14.PubMedGoogle Scholar
  9. 9.
    Varkey P, Jerath AU, Bagniewski SM, Lesnick TG. The epidemiology of tuberculosis among primary refugee arrivals in Minnesota between 1997 and 2001. J Travel Med. 2007;14(1):1–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Taylor Z, Nolan CM, Blumberg HM, American Thoracic Society, Centers for Disease Control and Prevention, et al. Controlling tuberculosis in the United States Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2005;54(RR-12):1–81.Google Scholar
  11. 11.
    Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2010;59(Rr-5):1–25.Google Scholar
  12. 12.
    Cellestis. Quantiferon-TB Gold (in-tube method) package insert. 2006. Accessed 01 Dec 2014.
  13. 13.
    World Health Organization. Global tuberculosis report 2013. Geneva. 2013. Accessed 28 Aug 2014.
  14. 14.
    Drobniewski F, Balabanova Y, Zakamova E, Nikolayevskyy V, Fedorin I. Rates of latent tuberculosis in health care staff in Russia. PLoS Med. 2007;4(2):e55.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shah M, DiPietro D, Greenbaum A, Ketemepi S, Martins-Evora M, Marsiglia V, et al. Programmatic impact of QuantiFERON-TB gold in-tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012;7(5):e36551.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Levesque JF, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis. 2004;8(6):711–7.PubMedGoogle Scholar
  17. 17.
    Trauer JM, Krause VL. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust. 2011;194(11):579–82.PubMedGoogle Scholar
  18. 18.
    Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of latent tuberculosis infection treatment adherence among refugees and other patient groups referred to the Baltimore City Health Department TB Clinic, February 2009–March 2011. J Immigr Minor Health. 2015;17(1):56–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235–54.PubMedGoogle Scholar
  20. 20.
    Butcher K, Biggs BA, Leder K, Lemoh C, O’Brien D, Marshall C. Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients. BMC Res Notes. 2013;6:342.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Abraham BK, Winston CA, Magee E, Miramontes R. Tuberculosis among Africans living in the United States, 2000–2009. J Immigr Minor Health. 2013;15(2):381–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6):1712–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Centers for Disease Control, Prevention. Impact of a shortage of first-line antituberculosis medication on tuberculosis control—United States, 2012–2013. MMWR Morb Mortal Wkly Rep. 2013;62(20):398–400.Google Scholar
  27. 27.
    Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14(5):551–9.PubMedGoogle Scholar
  28. 28.
    Centers for Disease and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–3.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Communicable Disease ServicesMultnomah County Health DepartmentPortlandUSA

Personalised recommendations